Exclusive: FDA’s new head of device safety's industry ties

Also: Novo's new obesity drug shows modest results, raises concerns of psychiatric side effects

September 20, 2024 Check out STAT+

Sponsored By

Correction: Yesterday's newsletter misspelled Francis Collins' name.

LISELOTTE SABROE/Scanpix/AFP via Getty Images STAT+ | Novo's new obesity drug shows modest results, raises concerns of psychiatric side effects The results pose a challenge to the pharma giant's efforts to find novel obesity drugs following the success of its blockbuster Wegovy. By Elaine Chen STAT+ | FTC sues big 3 PBMs for 'artificially inflated' insulin prices caused by 'perverse' rebating The FTC argued CVS Caremark, Cigna's Express Scripts, and UnitedHealth's OptumRx 'lined their pockets' at the expense of patients. By Ed Silverman STAT+ | Amazon cuts ties with fertility benefits company Progyny Amazon will offer its employees fertility benefits from a new vendor next year. By Bob Herman Joe Raedle/Getty Images FDA approves first at-home flu vaccine in U.S., a nasal spray Starting next flu season, people who want to order the vaccine to give it to themselves or their children at home will be able to do so. By Helen Branswell STAT+ | FDA's new head of device safety held senior role at company troubled by safety warnings Ross Segan was previously a senior exec at Olympus, which makes medical scopes. By Lizzy Lawrence STAT+ | FDA approves first drug for rare neuron disease, Niemann-Pick type C Parents pushed for years for treatments for the neuron disorder Niemann-Pick type C. After setbacks, one drug now has FDA approval. By Jason Mast Courtesy Ginkgo Bioworks STAT+ | Ginkgo Bioworks bets on protein AI model and data generation to turn struggling company around Ginkgo executives say its new offerings provide an opportunity where it can clearly compete. But experts and analysts aren't so sure. By Brittany Trang and Jason Mast

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser